The agreement includes a legal framework for various collaboration projects between the two companies, covering research, development and commercialisation as well as advisory services.
The financial terms of the agreement have not been disclosed.
Companion diagnostics are expected to improve patient care and reduce health care costs by matching specific therapies to the individuals as all patients do not respond in the same way.
The agreement follows an earlier announcement from Dako introducing a master framework agreement between itself and Eli Lilly and Company, which focuses on developing novel companion diagnostics for Lilly’s oncology pipeline.